Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives $8.25 Consensus Target Price from Brokerages

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has earned an average recommendation of “Hold” from the six research firms that are currently covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $8.20.

A number of equities analysts have issued reports on RXRX shares. KeyCorp decreased their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a report on Wednesday, January 8th. Needham & Company LLC reissued a “buy” rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 8th. Leerink Partners decreased their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a research note on Friday, February 28th. Cowen reaffirmed a “hold” rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Finally, Morgan Stanley dropped their target price on Recursion Pharmaceuticals from $10.00 to $8.00 and set an “equal weight” rating on the stock in a report on Thursday, April 10th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Decker Retirement Planning Inc. purchased a new position in shares of Recursion Pharmaceuticals in the 4th quarter worth $26,000. Private Trust Co. NA purchased a new position in shares of Recursion Pharmaceuticals in the fourth quarter worth approximately $27,000. GAMMA Investing LLC raised its position in Recursion Pharmaceuticals by 1,979.2% in the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after acquiring an additional 4,948 shares during the period. Farther Finance Advisors LLC grew its position in shares of Recursion Pharmaceuticals by 21.1% during the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock valued at $52,000 after acquiring an additional 1,353 shares during the period. Finally, NewEdge Advisors LLC increased its stake in shares of Recursion Pharmaceuticals by 43.7% in the 4th quarter. NewEdge Advisors LLC now owns 7,847 shares of the company’s stock worth $53,000 after purchasing an additional 2,387 shares in the last quarter. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Trading Down 4.3 %

NASDAQ RXRX opened at $5.51 on Thursday. The firm has a market cap of $2.21 billion, a PE ratio of -3.60 and a beta of 1.00. Recursion Pharmaceuticals has a 1-year low of $3.79 and a 1-year high of $12.36. The stock has a 50-day moving average of $6.78 and a 200-day moving average of $6.82. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $4.60 million during the quarter, compared to the consensus estimate of $19.04 million. During the same period in the previous year, the business earned ($0.42) earnings per share. The firm’s revenue for the quarter was down 57.8% compared to the same quarter last year. As a group, sell-side analysts forecast that Recursion Pharmaceuticals will post -1.57 EPS for the current year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.